US EditionPublished • loading... • Updated
Durham drugmaker clears key FDA hurdle for potential billion-dollar therapy
Summary by The Business Journals
1 Articles
1 Articles
Durham drugmaker clears key FDA hurdle for potential billion-dollar therapy
BioCryst Pharmaceuticals won FDA approval to expand its lead drug Orladeyo to children ages 2–11, opening a new pediatric market for the hereditary angioedema treatment. Orladeyo generated most of BioCryst’s $468 million in 2025 revenue and is projected to reach $1 billion in annual sales by 2029.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
